StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$119.39−1.74 (-1.44%)

Close on Nov 19, 2026Market cap $10.19BP/E –Yield –

Kymera Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Kymera Therapeutics

Kymera Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Kymera Therapeutics figures

See a number that looks wrong?